{"id":"standard-chemotherapy-chop-ritiximab","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Alopecia"},{"rate":"20-30","effect":"Infusion reactions (rituximab)"},{"rate":"20-30","effect":"Infection"},{"rate":"5-10","effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is a multi-agent chemotherapy regimen that damages DNA and disrupts cell division in rapidly dividing cancer cells. Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen on B cells, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Together, this combination targets both the malignant B-cell population and provides broad cytotoxic effects.","oneSentence":"CHOP chemotherapy combined with rituximab kills cancer cells through cytotoxic chemotherapy while rituximab targets CD20+ B cells via antibody-mediated cellular destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:05.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT00991211","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-01","conditions":"Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas","enrollment":549}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Endoxan(R), Cyclostin(R) = Cyclophosphamide","Adriamycin(R) Doxorubicin","Oncovin(R) Vincristine","Prednison","Rituxan(R), MabThera(R) = Rituximab"],"phase":"phase_3","status":"active","brandName":"Standard chemotherapy CHOP + Ritiximab","genericName":"Standard chemotherapy CHOP + Ritiximab","companyName":"University of Giessen","companyId":"university-of-giessen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP chemotherapy combined with rituximab kills cancer cells through cytotoxic chemotherapy while rituximab targets CD20+ B cells via antibody-mediated cellular destruction. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}